SCM
RNTX

Stonepine Capital Management’s Rein Therapeutics RNTX Stock Holding History

Stonepine Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Buy
+218,038
New +$264K 0.13% 78

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Stonepine Capital Management's RNTX Position: Q2 2026 in Review

Stonepine Capital Management opened a new position in Rein Therapeutics (RNTX) in Q2 2026: 218,038 shares worth $227K. The stake represents 0.13% of the portfolio and ranks #78 among its holdings.

60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Stonepine Capital Management held 218,038 shares of Rein Therapeutics worth $227K as of Q2 2026.
  • Rein Therapeutics was a new Stonepine Capital Management position in Q2 2026.
  • Rein Therapeutics made up 0.13% of Stonepine Capital Management's portfolio in Q2 2026, its #78 holding.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.